Advertisement
ALT vs FLNA
Which Stock Would AI Choose? Altimmune (ALT) vs. Filana Therapeutics (FLNA) Stock Comparison
Key Takeaways
- ALT (Altimmune) and FLNA (Filana Therapeutics) are both pre-revenue, clinical-stage biotechnology companies, making them sensitive to trial data and regulatory milestones rather than earnings fundamentals.
- Altimmune is advancing pemvidutide, a late-stage GLP-1 (glucagon-like peptide-1)/glucagon dual agonist, across liver-disease indications, while Filana Therapeutics is refocusing its lead asset simufilam on TSC (tuberous sclerosis complex)-related epilepsy.
- Both stocks have traded well below their 52-week highs in recent months, reflecting broader risk-off sentiment toward speculative, development-stage biotech names.
- Altimmune holds a substantially larger cash position and market capitalization, while Filana Therapeutics has a much smaller balance sheet and a recently lifted FDA (Food and Drug Administration) clinical hold as a key catalyst.
- Sell-side consensus currently leans more constructively on ALT than on FLNA, though both names carry elevated clinical and execution risk.
- For further detail, explore ALT Major News and ALT Today's Price Move, as well as FLNA Major News and FLNA Today's Price Move.
- To see how automated systems are currently positioning across the market, explore the Trending AI Robots page.
Introduction
Altimmune and Filana Therapeutics occupy the same corner of the equity market: development-stage biotechnology companies with no marketed products and no meaningful revenue. Both derive their valuation almost entirely from the progress of a single lead clinical program. That shared profile makes this a useful stock comparison for investors and traders evaluating relative performance, catalysts, and market positioning within a volatile sector. Where the two differ is in their disease focus, balance-sheet strength, and the stage of their respective pipelines. Investors weighing these names are typically assessing clinical-trial risk tolerance, cash runway, and the odds that a pivotal readout can re-rate a stock.
ALT Overview and Recent Performance
Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, focused on liver diseases. Its lead candidate, pemvidutide, is an investigational dual GLP-1/glucagon receptor agonist being developed for MASH (metabolic dysfunction-associated steatohepatitis), AUD (alcohol use disorder), and ALD (alcohol-associated liver disease). In recent weeks the company has moved into late-stage development, initiating a global Phase 3 registrational program in MASH and reporting that its mid-stage AUD study met its primary endpoint. These milestones follow the FDA's grant of Breakthrough Therapy designation to pemvidutide for MASH earlier in the year.
Despite the pipeline progress, the stock has traded near the lower end of its 52-week range in recent market activity, pressured by sector-wide de-risking and the absence of near-term commercial revenue. The company ended its most recent quarter with roughly $519 million in cash and short-term investments, which management expects to fund operations into 2029. Analysts maintain a predominantly positive consensus on ALT, though the shares continue to reflect meaningful binary clinical risk.
FLNA Overview and Recent Performance
Filana Therapeutics, Inc., formerly Cassava Sciences, is a clinical-stage biotechnology company based in Austin, Texas, focused on CNS (central nervous system) disorders. The company rebranded and changed its ticker to FLNA in March 2026, aligning its identity with its lead candidate simufilam, which is designed to modulate the filamin A protein. The program's near-term focus has shifted toward TSC-related epilepsy, an area of high unmet medical need.
Recent weeks brought a notable regulatory catalyst: the FDA lifted a clinical hold on simufilam, enabling a Phase 2a study in TSC-related epilepsy, with patient screening expected to begin in early 2027. The shares nevertheless have traded near multi-month lows, and the company's market capitalization remains small relative to peers. Filana ended its latest quarter with a leaner cash position than Altimmune and a narrower operating-expense profile, as it works to advance its program with a focus on capital efficiency.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's automated trading systems. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, but only those most suitable for current market conditions earn a place in this featured section. These bots span a wide range of trading styles, strategies, timeframes, and performance statistics, each configured around its own set of tickers and risk parameters. Because the list is refreshed to reflect shifting market environments, it offers a snapshot of where algorithmic systems are currently finding opportunity. Investors and traders interested in how AI-driven approaches are navigating the present landscape can browse the section to evaluate the bots that align with their objectives.
Head-to-Head Comparison
The most visible contrast between these two names is scale. Altimmune carries a materially larger market capitalization and a cash position measured in the hundreds of millions of dollars, supporting a multi-year runway and a Phase 3 program. Filana Therapeutics operates with a far smaller balance sheet and market value, and its lead asset is earlier in clinical development within a narrower therapeutic niche. That distinction shapes both risk and reward: a larger balance sheet reduces near-term financing overhang, while a smaller company can re-rate sharply on a single positive readout.
The two also diverge on momentum and sentiment. Altimmune has converted positive trial data into late-stage progress and multiple analyst price targets, whereas Filana Therapeutics is rebuilding credibility after a rebrand and a regulatory hold, with its key catalyst still ahead. Sector exposure differs as well—ALT sits within the highly competitive metabolic and liver-disease arena, while FLNA targets a rare, underserved epilepsy indication with fewer direct competitors. Both remain vulnerable to clinical failure, dilution, and broad biotech risk-off conditions.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, and the stage and frequency of catalysts, Tickeron's AI would currently lean toward ALT. Altimmune's larger cash runway, its progression into a Phase 3 registrational study, a positive mid-stage readout, and a more constructive sell-side consensus together suggest relatively stronger positioning. Filana Therapeutics offers a potentially higher-beta opportunity tied to its recently cleared clinical path, but its smaller capital base and earlier-stage program introduce greater uncertainty. This is a probabilistic assessment of relative positioning rather than a prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and FLNA is a Hold.
ALT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ALT turned positive on November 02, 2026. Looking at past instances where ALT's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALT's RSI Oscillator exited the oversold zone, 37 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 70 cases where ALT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +7.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALT as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ALT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. ALT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.853) is normal, around the industry mean (3.498). P/E Ratio (-2.737) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (1678.863) settles around the average of (130.981) among similar stocks. ALT's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FLNA's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for FLNA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 36 of the 37 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where FLNA advanced for three days, in 191 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
FLNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FLNA as a result. In 77 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FLNA turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 41 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 10-day moving average for FLNA crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for FLNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.344) is normal, around the industry mean (3.498). P/E Ratio (-0.520) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.320) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. FLNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ALT | FLNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 57 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 98 | |
PRICE GROWTH RATING 1..100 | 81 | 92 | |
P/E GROWTH RATING 1..100 | 16 | 9 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FLNA's Valuation (57) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALT (94) in the Miscellaneous Commercial Services industry. This means that FLNA’s stock grew somewhat faster than ALT’s over the last 12 months.
FLNA's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that FLNA’s stock grew similarly to ALT’s over the last 12 months.
ALT's SMR Rating (96) in the Miscellaneous Commercial Services industry is in the same range as FLNA (98) in the Pharmaceuticals Other industry. This means that ALT’s stock grew similarly to FLNA’s over the last 12 months.
ALT's Price Growth Rating (81) in the Miscellaneous Commercial Services industry is in the same range as FLNA (92) in the Pharmaceuticals Other industry. This means that ALT’s stock grew similarly to FLNA’s over the last 12 months.
FLNA's P/E Growth Rating (9) in the Pharmaceuticals Other industry is in the same range as ALT (16) in the Miscellaneous Commercial Services industry. This means that FLNA’s stock grew similarly to ALT’s over the last 12 months.
| ALT | FLNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 88% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 80% |
| Declines ODDS (%) | 10 days ago 88% | 7 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALT’s FA Score shows that 1 FA rating(s) are green while FLNA’s FA Score has 1 green FA rating(s).
- ALT’s FA Score: 1 green, 4 red.
- FLNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALT’s TA Score shows that 5 TA indicator(s) are bullish while FLNA’s TA Score has 4 bullish TA indicator(s).
- ALT’s TA Score: 5 bullish, 3 bearish.
- FLNA’s TA Score: 4 bullish, 5 bearish.
Price Growth
ALT (@Biotechnology) experienced а -4.90% price change this week, while FLNA (@Biotechnology) price change was -18.85% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ALT is expected to report earnings on Nov 12, 2026.
FLNA is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALT has been loosely correlated with OGEN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then OGEN could also see price increases.
| Ticker / NAME | Correlation To ALT | 1D Price Change % | ||
|---|---|---|---|---|
| ALT | 100% | -8.49% | ||
| OGEN - ALT | 54% Loosely correlated | -3.30% | ||
| INDP - ALT | 45% Loosely correlated | -7.35% | ||
| FLNA - ALT | 45% Loosely correlated | -2.03% | ||
| DNLI - ALT | 44% Loosely correlated | -2.36% | ||
| EDIT - ALT | 44% Loosely correlated | -8.91% | ||
More | ||||
FLNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, FLNA has been loosely correlated with ALT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if FLNA jumps, then ALT could also see price increases.
| Ticker / NAME | Correlation To FLNA | 1D Price Change % | ||
|---|---|---|---|---|
| FLNA | 100% | -2.03% | ||
| ALT - FLNA | 45% Loosely correlated | -8.49% | ||
| SANA - FLNA | 43% Loosely correlated | -1.42% | ||
| JAGX - FLNA | 42% Loosely correlated | +0.14% | ||
| EDIT - FLNA | 42% Loosely correlated | -8.91% | ||
| DMAC - FLNA | 41% Loosely correlated | +0.21% | ||
More | ||||